Richard Davies is a senior commercial leader in the life sciences and healthcare sectors with global expertise in all aspects of sales and marketing, building businesses, driving long-term revenues, profit, market share growth and significant shareholder value, and developing/leading high-performing teams worldwide. He joined BONESUPPORT AB as CEO in 2016. He is Board Chair of Alvotech, Iceland. Mr Davies was VP/GM, Asia and Latin America at Amgen from 2010-2012. He previously served in global leadership roles at Eli Lilly, and worked for Spencer & Partners Consulting Engineers in London. He has a B.Sc. from Portsmouth University and an MBA from Warwick Business School.
Holdings in BONESUPPORT: 7,197,720 employee stock options.
Björn Westberg joined the Company as Chief Financial Officer in January 2017 from Recipharm AB (publ) - one of the largest pharmaceutical contract manufacturers in the world - where he was CFO since 2007. Prior to this Mr Westberg was CFO of the listed (Nasdaq Stockholm) software company Jeeves (2001-2007). Before that he held senior roles at AstraZeneca, among those Finance Director ISMO Northern Europe and Controller in Astra Japan.
Holdings in BONESUPPORT: 1,250,000 warrants.
Mats Ögren joined BONESUPPORT AB in October 2016, bringing with him more than 17 years’ experience working across HR, R&D and Change Management. He has worked in various HR management positions at AstraZeneca, SonyMobile Communications and Teknopol/Mobile Heights in Lund. Previous to that he worked for IBM and Ericsson internationally. Mr. Ögren holds a degree in Business Administration & Behavior Science from Stockholm University.
Holdings in BONESUPPORT: None.
Mr Johri develops and manages international sales with a focus on exponential revenue growth. He holds an MBA in Marketing from Syracuse University (1993) and a Bachelors of Commerce from Dehli University (1988). Prior to his current role, Mr Johri was Chief Commercial Officer (2009-2012), and prior to joining BONESUPPORT AB, was VP of EMEA Wright Medical (2007-2009) and Group Marketing Manager International at Boston Scientific 2002-2009.
Holdings in BONESUPPORT: 1,005,812 employee stock options.
Dr McFadden is responsible for the design and execution of the worldwide clinical trials for US regulatory approval at BONESUPPORT AB. She holds a Doctorate in Veterinary Medicine and a Bachelor of Arts in Biology. Dr McFadden was previously Director of Preclinical and Clinical Affairs at Lutonix Inc, a start-up that was acquired by CR Bard, 2007-2014; Preclinical Research Manager Boston Scientific 2003-2007; Research Scientist, Medtronic 1997-2003. She is still a practising veterinarian and active in local outreach projects.
Holdings in BONESUPPORT: 360,000 employee stock options.
Carin Nilsson-Thorell has overall responsibility for global quality and regulatory compliance. She has been VP, Quality & Regulatory Management, at BONESUPPORT AB since 2002. She holds an MSc in Chemical Engineering (1979) with academic post graduate courses in Medical Device Technology (Clinical Chemistry); Pharmacology and Toxicology.
Carin previously managed pre-clinical and clinical qualification of immune therapy medical devices at Glycorex Transplantation (2001-2002). Prior to this she worked at Gambro AB in various international positions within medical device development and qualification including a position as Director for Microbiology, Toxicology and Clinical Affairs (1980-2000); and as Laboratory Engineer at Clinical Chemistry lab at University Hospital (1978-1980).
Holdings in BONESUPPORT: 225,295 employee stock options.
Eva Lidén has an overall responsibility for the research and development in BONESUPPORT AB and she has been deeply involved in the development of the CERAMENT™ products. Eva joined BONESUPPORT AB in 2004 and was Research Manager, before she was appointed VP R&D in 2013. Eva holds an MSc in Chemical Engineering (1986) and PhD in Ceramic Technology (1996). Prior to this, Eva worked at the Swedish Ceramic institute from 1986 to 2004.
Holdings in BONESUPPORT: 245,765 employee stock options.
Linda Butcher joined BONESUPPORT AB in 2010 and is responsible for global marketing strategies and activities. Prior to this she worked in sales and product specialist roles for Schneider UK (1990-1998). From 1998 to 2010 she was European Marketing Manager and International Marketing Manager for Boston Scientific. Linda is a Registered General Nurse (RGN) and was previously VP Global Marketing, BONESUPPORT AB (2010-2016).
Holdings in BONESUPPORT: 421,550 employee stock options.
Dr. Diefenbeck joined BONESUPPORT AB in April 2017. In 2014 he founded Scientific Consulting in Orthopaedic Surgery and worked for BONESUPPORT AB on different projects as an independent clinical advisor. He is currently honorary consultant at Nuffield Orthopaedic Centre, Oxford University Hospitals. Dr. Diefenbeck studied medicine at Munich and was trained as an orthopaedic surgeon, specializing in trauma care and bone infections. He has 14 years’ clinical experience at different German hospitals (BG Unfallklinik Murnau, BG Kliniken Bergmannstrost Halle/Saale, University Hospital Jena and Schön Klinik Hamburg Eilbek). At University Hospital Jena he finished his PhD in 2011 and has since been involved in surgical education and training programs for students. He is author of 24 Pub-med listed research articles.
Holdings in BONESUPPORT: 360,000 employee stock options.
Johan Olsson is responsible for supply chain and holds an MSc in Mechanical Engineering (1991) from Lund University. He joined BONESUPPORT AB in 2007 as production and logistics Director, and before then he worked for Gambro as Head of the Intensive Care Line (2000-2007), where he was responsible, amongst other things, for the transfer of Gambro's production in Italy to Sweden. Before that, Johan held a number of different logistics, purchasing and manufacturing management positions in various consumer product companies.
Holdings in BONESUPPORT: 165,295 employee stock options.
Patrick O’Donnell has a proven track record in the medical device, biologics, and biomaterials industries - with technologies in the orthopedic, spine, neurosurgery, sports medicine, interventional radiology, vascular and, metabolic disorders markets – gained over the past 24 years. Mr. O’Donnell most recently served as the Founder, Director, and Chief Executive Officer of ProteoThera, Inc., an early stage biotech company with matrix-binding protein fusion technology for local delivery of small molecules and proteins to address articular joint inflammatory diseases. Prior to this he held the position of CEO at several organizations including EndoSphere Inc, Histogenics Corporation and Prochon BioTech; and the Director of Global Marketing at Confluent Surgical. Mr. O’Donnell began his career at J & J DePuy Spine where he worked for thirteen years in commercial positions of escalating responsibility. Mr. O’Donnell graduated from the University of Wisconsin-Madison.
Holdings in BONESUPPORT: 720,000 employee stock options.